What is Mg Biologics?
Mg Biologics, headquartered in Ames, Iowa, is a licensed antibody manufacturer specializing in plasma and antibody products for a diverse range of animal species, including equine, canine, bovine, and porcine. The company's product portfolio encompasses critical treatments such as antivenom and IgG products, alongside custom blends designed to bolster animal health from neonatal stages through critical care. Mg Biologics' commitment to research and development drives its mission to provide tailored solutions, addressing the vital role of antibodies in mitigating disease severity and duration. Their offerings, like the Rattler Antivenom, exemplify their dedication to effective veterinary care.
How much funding has Mg Biologics raised?
Mg Biologics has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Mg Biologics?
The substantial late-stage funding positions Mg Biologics for significant growth and strategic initiatives. This capital infusion is likely to fuel advancements in research and development, potentially expanding their product lines or entering new markets. The company's focus on specialized antibody production for animal health suggests a trajectory aimed at solidifying its leadership in veterinary therapeutics and enhancing its global reach through strategic partnerships or acquisitions.
See full Mg Biologics company page
